Tissue Diagnostics Market Worth 5.14 Billion USD by 2022

Manish Arya / On 2017-11-10 04:29:01

According to a new market research report "Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology & Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End User (Hospital, CRO) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 5.14 Billion by 2022 from USD 3.68 Billion in 2017, at a CAGR of 6.9%. Factors driving the growth of this market include the rising incidence of cancer, growing healthcare expenditure, improving infrastructure for cancer diagnosis, and technological advancements in tissue diagnostics.

By product, the Tissue Diagnostics Market is classified into instruments and consumables. The consumables segment is expected to lead the global Tissue Diagnostics Market in 2017. Factors driving the growth of this segment include the wide use of consumables for processing tissue samples, ease of use, and cost-effectiveness.

By technology, the market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry technology segment is expected to account for the largest share of the global Tissue Diagnostics Market in 2017. A large number of products are based on this technology which is a major factor responsible for the dominant share of this segment.

On the basis of end users, the Tissue Diagnostics Market is categorized into hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users. The hospitals segment is estimated to account for the largest share of the global Tissue Diagnostics Market during the forecast period. The heavy burden of different cancers, along with the accessibility and availability of test results in hospitals in a short period of time are the key factors driving the growth of this end-user segment.

Based on region, the Tissue Diagnostics Market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to dominate the Tissue Diagnostics Market in 2017. This is attributed to factors such as accessibility to advanced technologies and opportunities for advanced cancer diagnostic testing and screening, growing incidence of cancer, and technological advancements of tissue diagnostics products in the region as compared to other regions.

Key players in the Tissue Diagnostics Market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), Merck (Germany), Sakura Finetek Japan (Japan), Abcam (UK), BD (US), QIAGEN (Netherlands), Sienna Cancer Diagnostics (Australia), Royal Philips (Netherlands), A. Menarini Diagnostics (Italy), Cell Signaling Technology (US), Enzo Life Sciences (US), Master Diagnóstica (Spain), TissueGnostics (Austria), Bio SB (US), MedImmune (US), Cernostics (US), Zenalux Biomedical (US), 3DHISTECH (Hungary), Lunaphore Technologies (Switzerland), BioGenex (US), and Biocare Medical (US).

Related Stories